Coenzyme Q10 Role in Prevention of Contrast Induced Nephropathy in Acute Coronary Syndrome Patients.

Ain Shams University

Status and phase: Enrolling; Phase 4

Conditions: Contrast-induced Nephropathy

Treatments: Drug: Placebo; Drug: Coenzyme Q10 100 Milligrams Oral Capsule

Study type: Interventional

Funder types: Other

Identifiers

NCT06429345

MS70/2024

Details and patient eligibility

About

In this study the investigators aim to study the effect of supplementation of CoQ10 in decreasing the incidence of contrast induced acute kidney injury in patients with acute coronary syndrome undergoing coronary angiography.

Full description

Patients who fulfilled the inclusion criteria and agreed to participate in the study will be randomly divided into 2 groups using their computer generated random numbers that group a will receive the coenzyme Q10 in addition to the standard preventive measures and group b will receive only the standard preventive measures without the coenzyme Q10.

Enrollment: 250 estimated patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Patients who are 18 years or older.
• ST-elevation myocardial infarction (STEMI).
• Non ST-elevation myocardial infarction( NSTEMI).
• Unstable Angina (UA)

Exclusion criteria

• Renal transplant patients.
• Preoperative bleeding .
• Intraoperative bleeding or hypotension.
• Patients taking any nephrotoxic medications

Trial design

Primary purpose: Prevention

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Quadruple Blind

---

250 participants in 2 patient groups, including a placebo group

Coenzyme Q10 100 Milligrams Oral Capsule

Experimental group

Description:

Coenzyme Group received coenzyme Q10 in addition to the the standard preventive measures

Treatment:

Drug: Coenzyme Q10 100 Milligrams Oral Capsule

Placebo group

Placebo Comparator group

Description:

Placebo Group received only the standard preventive measures

Treatment:

Drug: Placebo